Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While sales of key drugs Vivitrol and Aristada continue to grow rapidly, Alkermes' overall revenue growth came in much weaker than expected. As a result, management dialed back its revenue growth expectations for the full year. However, containment efforts helped the company to beat expectations on the bottom-line.
Data source: Alkermes. GAAP = generally accepted accounting principles.
Image source: Getty Images.
Source: Fool.com
Alkermes plc Aktie
42,58 €
-1,91 %
Klarer Community-Favorit: Alkermes plc mit vielen Buy- und wenigen Sell-Einschätzungen.
Ein Kursziel von 46 € für Alkermes plc impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 42.58 €.
